SLG-100

N/A

Report date: 2026/03/09 20:02:04

Base Information

Drug NameSLG-100
Drug Alias NameOcular Surface ImmunoglobulinGRF312 Ophthalmic SolutionOcular surface immunoglobulin (OSIG)SLG-100GRF-312 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionCytokines inhibitorsInflammation mediators inhibitors
TargetsCytokinesInflammation mediators
Therapy Area/IndicationsDry Eye SyndromesXerophthalmia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSelagine Inc
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Grifols Sa
Inactive CompaniesUniversity Of Illinois At Chicago
Active IndicationsDry Eye Syndromes
Inactive IndicationsXerophthalmia

Other Information

ATC CodeN/A
Related LinksN/A